ABSTRACT
INTRODUCTION
Phosphatase homologue of tensin (PTEN) is one of the most commonly associated mutated genes in prostate cancer, and its mutation is tightly correlated to poor clinical prognosis (Sircar et al., 2009 ). This protein functions as an endogenous intracellular modulator of the phosphoinositide-3-kinase (PI 3 K)-Akt pathway and therefore plays a central role in regulating proliferation in many epithelial cells (Cantley and Neel, 1999) . A key regulatory step in this cascade is phosphorylation of phosphoinositide-bisphosphate (PIP 2 ) to generate PIP 3 by PI 3 K, resulting in activation of phosphoinositide-dependent kinases (PDK) and activation of Akt by phosphorylation (Cantley and Neel, 1999) . PTEN acts as a phosphoinositide phosphatase to reverse this reaction and inhibit PI 3 K-Akt signaling (Cantley and Neel, 1999) . Therefore reduced expression or function of PTEN in cancer permits unregulated Akt activation and increased tumor cell proliferation (Groszer et al., 2001; Halvorsen et al., 2003) . Numerous mitogens and cytokines impinge upon this pathway by activating secondary adaptor molecules such as src, focal adhesion kinase (FAK), and insulin-like receptor substrate (IRS) that initiate the PI 3 K-Akt signaling cascade (Frost and Lang, 2007; Arcaro et al., 2007; Xia et al., 2004; Ozes et al., 2001 ).
Studies of growth regulatory pathways in the developing prostate have identified a number of important morphogens including fibroblast growth factors, hedgehog ligands, cytokines including interleukins and transforming growth factor beta, Notch, wnt/beta-catenin and the bone morphogenetic proteins (BMPs) (Prins and Putz, 2008) . The BMPs are members of the TGF-beta superfamily and over 20 BMP ligands have been identified (Gazzerro and Canalis, 2006) . The BMPs act by binding heterodimers of BMPR type II and type I receptors activating members of the SMAD family of signaling intermediates, most particularly SMADs 1, 5, and 8 (Gazzerro and Canalis, 2006) . The readout of BMP signaling is phosphorylation of SMADs and changes in transcription of specific target genes (Gazzerro and Canalis, 2006) . Previous studies have shown that the ligands BMP-4 (and its homolog BMP-2) and BMP-7 are expressed in the developing prostate and exert important effects on prostate growth and proliferation (Lamm et al., 2001; Grishina et al., 2005) . Interestingly, expression of BMP-2, 4, and 7 ligands, BMP receptors and intracellular signaling components is diminished in prostate cancer as compared to normal tissue, and BMPs have been shown to inhibit prostate cancer cell line proliferation and tumor growth (Miyazaki et al., 2004; Brubaker et al., 2004; Kim et al., 2004) .
Although it is widely accepted that genetic mutation of PTEN can contribute to tumor tumorgenesis, recent studies suggest regulation of PTEN expression and activity may also contribute to tumor growth (Tamguney and Stokoe, 2007) . For example, studies have shown that PTEN protein expression is reduced in a significant number of breast cancers (Engin et al., 2006) .
Although, the precise mechanism behind reduced PTEN protein levels in these cancers is poorly understood, repression of PTEN expression as well as changes in the activity and stability of PTEN protein have been proposed. Multiple signals could lead to positive or negative modulation of PTEN expression, including TGFβ signaling, UV radiation, and EGR-1 and PPAR signaling (Li and Sun, 1997; Stiles, 2009) . Interestingly, BMP signaling has been demonstrated to sustain PTEN expression in the colon (Waite and Eng, 2003) . Given the concurrent loss of expression of PTEN and BMP commonly observed in prostate cancer, we sought to investigate a possible mechanistic relationship between these pathways. The LNCaP prostate cancer cell line is generally considered to be PTEN negative and no induction of PTEN expression or change in Akt activation was observed in LNCaP cells treated with BMP-4 (data not shown). Overexpression of PTEN in LNCaP-derived C4-2 cells consistently reduces proliferation, suggesting that PTEN activation is sufficient to inhibit growth (Wu et al., 2007) . C4-2 cells engineered to express active PTEN from a doxacyclin-driven promoter exhibit a concentration-dependent inhibition of cell proliferation by doxacyclin (Wu et al., 2007) . We treated these cells with increasing concentrations of doxacyclin in semi-log increments in the presence or absence of 10 ng/ml BMP-4 to examine the interaction of BPM-4 and PTEN [ Figure   3A ]. BMP-4 did not inhibit proliferation of cells lacking significant promoter-driven PTEN expression (0 to 0.1 mg/ml doxacyclin). Intermediate concentrations of doxacyclin (0.3 μg/ml and 1.0 μg/ml doxacyclin) produced partial growth inhibition that was significantly augmented by BMP treatment as evidenced by a log-fold leftward shift in the concentration-response curve.
RESULTS

We
However, cells lacking significant promoter-driven PTEN expression (0 to 0.1 mg/ml doxacyclin) did not respond to BMP, and BMP failed to produce further growth inhibition in cells with full PTEN promoter-driven expression (3 mg/ml doxacyclin). The effect of BMP on growth inhibition was mirrored by PTEN protein induction. [ Figure 3B ] These data indicate that partial promoterdriven PTEN expression is necessary for BMP-4 to significantly affect growth rate in C4-2 cells. Figure 5A ] This is not associated with an increase in mRNA stability for PTEN message, indicating that BMP-4 is likely inducing PTEN at the transcriptional level. In addition, BMP-4 treatment is associated with a rapid decrease in phosphorylated PTEN protein levels (residues 380, 382, and 383), despite an evident increase in total PTEN levels. [ Figure 5C ]. To investigate the effect of BMP treatment on PTEN protein stability, we treated E6 cells pre-exposed to either BMP-4 or vehicle with cyclohexamide (5 μM) for 0, 0.5, 1, 1.5, 2, 3, 4, 8, or 24 hours and measured PTEN protein levels. We found that 24 hours of BMP pretreatment caused a doubling in PTEN half-life (15.1 hours to 28.4 hours, p=0.03, n=4). [ Figure 5D ] These data indicate that BMP-4 has a dual effect on PTEN expression that involves increased expression and enhanced protein stability.
DISCUSSION
To our knowledge, this is the first paper to report on the mechanism by which bone morphogenetic proteins mediate prostate cell proliferation rates. The data indicate that treatment of prostate cell lines with BMP-4 results in increased cellular PTEN concentrations and a corresponding decrease in PI 3 K-Akt signaling. The data further show that PTEN increase is at least in part responsible for the decreased proliferation rate observed in prostate cell lines since siRNA knockdown of PTEN expression attenuates BMP-mediated decreases in cellular proliferation. PTEN increase involves both transcriptional and post-translational mechanisms, as a rapid increase in PTEN mRNA and an increase in PTEN protein stability were observed after BMP-4 treatment. Experiments with conditional PTEN over-expressing cell lines further support a role for PTEN stability in cellular proliferation, as these cells required previous promoter-driven PTEN expression in order to respond to BMP-4 by PTEN expression increases and decreases in proliferation. Further, a decrease in phosphorylation of PTEN at residues 380, 382, and 383 are suggestive of enhanced PTEN activity, as these residues have been implicated in enzymatic activity in previous reports (Rahdar, et al., 2009) . Future studies should be directed toward detailing the enzymatic effects of BMP signaling on PTEN function.
The BMP signaling pathway has critical roles in embryogenesis, organogenesis, cell growth, differentiation, cell migration and cell death (Miyazaki et al., 2003) . Due to the diversity of these biological functions, it is not surprising that BMPs have been associated with control of proliferation and differentiation in normal and malignant prostate epithelial cells (Miyazaki et al., 2004; Brubaker et al., 2004; Kim et al., 2004) . BMP-4 and BMP-7 are androgen-regulated genes that play critical roles in the proper regulation of prostate development by inhibiting epithelial proliferation, ductal budding and branching (Grishina et al., 2005) . Specifically, BMP signaling is believed to promote differentiation of prostate epithelial cells, thereby repressing proliferative capacity (Grishina et al., 2005; Cook et al., 2007) . In addition, the BMP antagonist Noggin is expressed in the developing mouse prostate and neutralizes inhibition of epithelial proliferation by BMP4 allowing ductal budding and regulation of bud outgrowth (Cook et al., 2007) . Our data suggest that in depth study of a possible interplay of BMP and PTEN / PI 3 K-Akt signaling is warranted to further the mechanistic understanding of BMP signaling in prostate development.
With regard to prostate cancer however, divergence in expression and function among the BMPs is evident in published reports and there are considerable inconsistencies in published results regarding the biological function of BMPs in prostate cancer cells. For example, BMP-6 expression is upregulated in prostate cancers relative to noncancerous epithelium (Darby et al., 2008) , while BMP-2, BMP-4, and BMP-7 expression is decreased (Masuda et al., 2004 ). Yet, BMP-4, BMP-6 and BMP-7 have all been consistently detected in prostate cancer bone metastases and expression of proteins involved in the BMP signaling pathway are often observed in metastatic prostate cancer (Feeley et al., 2005) . While several reports show a growth-reducing and differentiating effect of BMPs similar to what occurs in prostate development, other findings support a tumor-promoting role (Yang et al., 2005; Ye et al., 2007) . These inconsistencies illustrate a pronounced uncertainty in this field, and the data presented in this manuscript may contribute to resolving some of these uncertainties. Specifically, the PTEN status of a particular tumor may be critical in determining how that tumor may respond to BMP expression: a PTENpositive cell may respond in growth inhibitory/pro-differentiation direction while a PTENnegative cell may respond in the opposite direction. While it is well-established that PTEN loss of function or suppression of expression is associated with prostate cancer growth and progression, recent papers have begun to define a role for PTEN in prostate cell migration and metastases (Wu et al., 2007) . Cell migration in PTENnegative C4-2 cells is inhibited by ectopic PTEN expression and is dependent upon activity of the lipid phosphatase function of PTEN and corresponding decrease in PI 3 K-Akt signaling (Wu et al., 2006) . 23 Similarly, PTEN-deficient cells exhibit increased cell motility, and PI 3 K-Akt signaling plays an important role in the regulation and directionality of cell migration (Shukla et al., 2007) .
In addition, bladder cancer cells exhibit PI 3 K-Akt-dependent epidermal growth factor-mediated chemotaxis (Gu et al., 1999; Theodorescu et al, 1998 ). Our data demonstrate that BMP signaling, 
MATERIALS / SUBJECTS AND METHODS
Cells and culturing conditions: E6 prostate epithelial cells were kind gifts from Dr. David
Jarrard, Department of Urology, University of Wisconsin Madison, and were cultured in conditions as previously published (Schwarze et al., 2002) . 21 The immortalized cells were screened for HPV16 E6 protein expression by Western blot analysis and were cultured for over 20 passages to confirm immortality. BPH-1 cells were kindly provided by Dr. Simon Hayward,
Vanderbilt University, Nashville, TN and were grown and maintained in conditions previously published (Hayward et al., 1995) . The doxycyclin (DOX)-inducible C4-2 primary cell line (C4-2 pTetOn) cells were generated by Dr. Zhong Wu under the supervision of Dr. Dan Theodorescu and have been previously described (Wu et al., 2006) . Cells were generated by transfection of pTRE2hyg PTEN-HA into C4-2 pTetOn cells; cells were maintained in 10% FBS/RPMI 1640 medium. Growth rate and PTEN inducibility experiments were performed in these cells and those expressing a scrambled sequence siRNA previously shown not to effect gene expression by Open
Growth rate determinations:
Biosystems.
RT-PCR of mRNA levels: Prostate cell lines were grown to 90% confluency in 12 well plates using cell line-specific conditions as described above and treated with either 10 ng/ml BMP-4 or vehicle (0.02% BSA in PBS) for 2, 4, 8, or 24 hours. Cells were harvested in 350 μl Qiagen RNeasy RLT lysis buffer plus 2-mercaptoethanol, RNA was extracted using the RNeasy kit as directed by the manufacturer (Qiagen, Valencia, CA), and complementary DNA was made using reverse transcription as previously described (Jerde and Bushman, 2009 ). RT-PCR for PTEN expression was performed as published (Jerde and Bushman, 2009) Inhibition of the 26S proteosome with 10 μM MG-132 results in similar protein stabilization effects on PTEN (not shown).
